Drug intelligence / Profile preview

SIR-T EGFRvIII

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T EGFRvIII is an experimental cell therapy being developed by Angeles Therapeutics for the treatment of cancers expressing the Epidermal Growth Factor Receptor variant III (EGFRvIII) mutation, such as glioblastoma. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which involves engineering T cells to express a receptor designed to mimic the natural T-cell receptor (TCR) signaling complex. This approach is intended to provide more physiological T-cell activation and improved persistence compared to traditional Chimeric Antigen Receptor (CAR) T-cell therapies. The program is currently in the discovery stage of development.

Other names: SIR-T EGFRvIII

Targets

EGFRvIII (Epidermal growth factor receptor variant III)

Beyond the preview

Go deeper on SIR-T EGFRvIII.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T EGFRvIII.

Explore the full profile